SAL003 clinical trials
How each study uses SAL003 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- SAL003 140 mg
- 2
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses SAL003 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of SAL003 in Participants With Hypercholesterolemia and Mixed DyslipidemiaCompletedPhase 3Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT07295418Written as SAL003 140 mg
- A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed DyslipidemiaCompletedPhase 2Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT07278830Written as SAL003 140mg+Atorvastatin
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of SAL003 in Combination With Statin Therapy in Patients With Hypercholesterolemia and Mixed DyslipidemiaCompletedPhase 3Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT07253584Written as SAL003 140 mg